Literature DB >> 20607553

Factors influencing disease phenotype and penetrance in HFE haemochromatosis.

J Rochette1, G Le Gac, K Lassoued, C Férec, K J H Robson.   

Abstract

Haemochromatosis is predominantly associated with the HFE p.C282Y homozygous genotype, which is present in approximately 1 in 200 people of Northern European origin. However, not all p.C282Y homozygotes develop clinical features of haemochromatosis, and not all p.C282Y homozygotes even present abnormal iron parameters justifying venesection therapy. This situation was not apparent from initial genotype/phenotype correlation studies as there was a selection bias of patients. Only those patients with a significant iron burden were included in these early studies. It is now largely accepted that the p.C282Y/p.C282Y genotype is necessary for the development of HFE haemochromatosis. However, this genotype provides few clues as to why certain symptoms are associated with the disease. Expression of iron overload in people with this genotype depends on the complex interplay of environmental factors and modifier genes. In this review, we restrict our discussion to work done in humans giving examples of animal models where this has helped clarify our understanding. We discuss penetrance, explaining that this concept normally does not apply to autosomal recessive disorders, and discuss the usefulness of different biochemical markers in ascertaining iron burden. Hepcidin, a peptide synthesized primarily by the liver, has been identified as the central regulator in iron homeostasis. Consequently, understanding its regulation is the key. We conclude that the main goal now is to identify important modifiers that have a significant and unambiguous effect on iron storage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607553     DOI: 10.1007/s00439-010-0852-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  153 in total

1.  Homozygous deletion of HFE is the common cause of hemochromatosis in Sardinia.

Authors:  Gérald Le Gac; Rita Congiu; Isabelle Gourlaouen; Milena Cau; Claude Férec; Maria Antonietta Melis
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

2.  Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype.

Authors:  Gérald Le Gac; Isabelle Gourlaouen; Christophe Ronsin; Vanna Géromel; Anne Bourgarit; Nathalie Parquet; Sylvia Quemener; Cédric Le Maréchal; Jian-Min Chen; Claude Férec
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

3.  Haemochromatosis and HLA-H.

Authors:  E C Jazwinska; L M Cullen; F Busfield; W R Pyper; S I Webb; L W Powell; C P Morris; T P Walsh
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

4.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

Review 5.  Haemochromatosis in the new millennium.

Authors:  L W Powell; V N Subramaniam; T R Yapp
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

6.  TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis.

Authors:  Christoph H Osterreicher; Christian Datz; Felix Stickel; Claus Hellerbrand; Melitta Penz; Harald Hofer; Fritz Wrba; Edward Penner; Detlef Schuppan; Peter Ferenci
Journal:  Cytokine       Date:  2005-07-21       Impact factor: 3.861

Review 7.  Current approaches to the management of hemochromatosis.

Authors:  Pierre Brissot; Frédéric de Bels
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

8.  A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis.

Authors:  Marie-Laure Island; Anne-Marie Jouanolle; Annick Mosser; Yves Deugnier; Véronique David; Pierre Brissot; Olivier Loréal
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

9.  A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis.

Authors:  Clare C Constantine; Greg J Anderson; Chris D Vulpe; Christine E McLaren; Melanie Bahlo; Heng Lin Yeap; Dorota M Gertig; Nicholas J Osborne; Nadine A Bertalli; Kenneth B Beckman; Victoria Chen; Pavel Matak; Andrew T McKie; Martin B Delatycki; John K Olynyk; Dallas R English; Melissa C Southey; Graham G Giles; John L Hopper; Katrina J Allen; Lyle C Gurrin
Journal:  Br J Haematol       Date:  2009-08-10       Impact factor: 6.998

10.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

View more
  14 in total

Review 1.  Genome-wide association studies and genetic risk assessment of liver diseases.

Authors:  Marcin Krawczyk; Roman Müllenbach; Susanne N Weber; Vincent Zimmer; Frank Lammert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

2.  Epistasis in iron metabolism: complex interactions between Cp, Mon1a, and Slc40a1 loci and tissue iron in mice.

Authors:  Constance Delaby; Vincent Oustric; Caroline Schmitt; Francoise Muzeau; Anne-Marie Robreau; Philippe Letteron; Eric Couchi; Angel Yu; Saïd Lyoumi; Jean-Charles Deybach; Herve Puy; Zoubida Karim; Carole Beaumont; Bernard Grandchamp; Peter Demant; Laurent Gouya
Journal:  Mamm Genome       Date:  2013-12       Impact factor: 2.957

3.  Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling.

Authors:  Katarzyna Mleczko-Sanecka; Franziska Roche; Ana Rita da Silva; Debora Call; Flavia D'Alessio; Anan Ragab; Philip E Lapinski; Ramesh Ummanni; Ulrike Korf; Christopher Oakes; Georg Damm; Lorenza A D'Alessandro; Ursula Klingmüller; Philip D King; Michael Boutros; Matthias W Hentze; Martina U Muckenthaler
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

4.  Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.

Authors:  Karin E Finberg; Rebecca L Whittlesey; Nancy C Andrews
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

Review 5.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

6.  Effects of strain and age on hepatic gene expression profiles in murine models of HFE-associated hereditary hemochromatosis.

Authors:  Seung-Min Lee; Alexandre Loguinov; Robert E Fleming; Christopher D Vulpe
Journal:  Genes Nutr       Date:  2014-11-27       Impact factor: 5.523

7.  Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing.

Authors:  Yali Xue; Yuan Chen; Qasim Ayub; Ni Huang; Edward V Ball; Matthew Mort; Andrew D Phillips; Katy Shaw; Peter D Stenson; David N Cooper; Chris Tyler-Smith
Journal:  Am J Hum Genet       Date:  2012-12-07       Impact factor: 11.025

8.  Non-coding keratin variants associate with liver fibrosis progression in patients with hemochromatosis.

Authors:  Pavel Strnad; Ozlem Kucukoglu; Mariia Lunova; Nurdan Guldiken; Tim C Lienau; Felix Stickel; M Bishr Omary
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

Review 9.  Multi-copper oxidases and human iron metabolism.

Authors:  Ganna Vashchenko; Ross T A MacGillivray
Journal:  Nutrients       Date:  2013-06-27       Impact factor: 5.717

Review 10.  An update on laboratory diagnosis of liver inherited diseases.

Authors:  Federica Zarrilli; Ausilia Elce; Manuela Scorza; Sonia Giordano; Felice Amato; Giuseppe Castaldo
Journal:  Biomed Res Int       Date:  2013-10-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.